Drug intelligence / Profile preview

cobimetinib + paclitaxel

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **cobimetinib**, a selective MEK1 and MEK2 inhibitor, and **paclitaxel**, a taxane chemotherapy drug. Cobimetinib works by inhibiting the MAPK/ERK pathway, which is involved in cell proliferation. Paclitaxel stabilizes microtubules, preventing cell division. The combination is explored for its potential to enhance efficacy in cancers like triple-negative breast cancer and cervical cancer by overcoming resistance to taxanes through MEK inhibition.

Targets

TUBB (Tubulin (alpha and beta subunits))MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on cobimetinib + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cobimetinib + paclitaxel.

Explore the full profile